- Home
- VERO vs REVB Comparison
VERO vs REVB Comparison
Compare VERO & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERO
- REVB
- Stock Information
- Founded
- VERO N/A
- REVB 2020
- Country
- VERO Canada
- REVB United States
- Employees
- VERO N/A
- REVB N/A
- Industry
- VERO Medical/Dental Instruments
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- VERO Health Care
- REVB Health Care
- Exchange
- VERO Nasdaq
- REVB Nasdaq
- Market Cap
- VERO 2.4M
- REVB 2.3M
- IPO Year
- VERO N/A
- REVB N/A
- Fundamental
- Price
- VERO $0.31
- REVB $4.31
- Analyst Decision
- VERO
- REVB
- Analyst Count
- VERO 0
- REVB 0
- Target Price
- VERO N/A
- REVB N/A
- AVG Volume (30 Days)
- VERO 128.1K
- REVB 175.9K
- Earning Date
- VERO 03-31-2025
- REVB 03-21-2025
- Dividend Yield
- VERO N/A
- REVB N/A
- EPS Growth
- VERO N/A
- REVB N/A
- EPS
- VERO N/A
- REVB N/A
- Revenue
- VERO $67,200,000.00
- REVB N/A
- Revenue This Year
- VERO N/A
- REVB N/A
- Revenue Next Year
- VERO $4.95
- REVB N/A
- P/E Ratio
- VERO N/A
- REVB N/A
- Revenue Growth
- VERO N/A
- REVB N/A
- 52 Week Low
- VERO $0.28
- REVB $3.34
- 52 Week High
- VERO $1.59
- REVB $69.44
- Technical
- Relative Strength Index (RSI)
- VERO 38.70
- REVB 40.86
- Support Level
- VERO $0.30
- REVB $3.80
- Resistance Level
- VERO $0.32
- REVB $4.54
- Average True Range (ATR)
- VERO 0.02
- REVB 0.37
- MACD
- VERO -0.00
- REVB 0.18
- Stochastic Oscillator
- VERO 12.62
- REVB 68.13
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).